Clinical Trial Update: Bispecific Antibody Plus White Blood Cells in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating a bispecific antibody combined with white blood cells for recurrent or refractory glioblastoma multiforme has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma Multiforme

Drugs mentioned

• Bispecific antibody plus white blood cells

Snippet

Sponsor: Dartmouth-Hitchcock Medical Center | Conditions: Brain and Central Nervous System Tumors | Phase 1 | Status: COMPLETED